Sitewide
Clinical trials for diabetes drugs should measure outcomes important to patients
Most clinical trials for new diabetes drugs do not consider the impact medication will have on a patient's quality of life or other outcomes that are important to patients, such as the risk of developing complications associated with diabetes, according to a Mayo Clinic commentary in the current issue of the Lancet.
Similar Articles On This Topic:
- Most ongoing diabetes trials do not include outcomes important to patients
- Should drug companies be allowed to conduct their own clinical trials?
- Developing core outcome sets for clinical trials needs patient input
- Drugs are safe, active in patients normally ineligible for clinical trial
- Mice and men should have more in common in clinical trials
Popular Today:
Science 2.0:
- Don't Hate - Voters Were Born That Way, Say Psychiatrists
- Scare Pic Of Earth Water Visual Framing Or Global Warming Wake Up Call
- Finding My Religion: The New Intersection Of Christianity And Environmentalism
- Organic Spinach Recalled Over Salmonella Concerns
- Modern Squid Ink Unchanged From Jurassic Times
Recent Articles:
Read Us On Your Kindle:
Create Your Own Releases:
Post new comment